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Atrial ﬁbrillation is the most common arrhythmia encountered in clinical practice and
can result in signiﬁcant morbidity and mortality. Catheter ablation has become a feasible
therapeutic option for the management of this complex and challenging arrhythmia. In this
article, we have discussed the mechanism of atrial ﬁbrillation, diﬀerent imaging modalities
used for atrial ﬁbrillation ablation, diﬀerent ablation strategies targeting non-pulmonary
veins, complications associated with atrial ﬁbrillation ablation and its management,
alternative energy sources for ablation and new antiarrhythmic drugs.
(J Arrhythmia 2007; 23: 85–101)
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Introduction
Atrial ﬁbrillation (AF) is the most common
cardiac arrhythmia seen in clinical practice and
results in signiﬁcant morbidity, mortality and health-
care costs. Catheter ablation has emerged as an
important treatment strategy for the eradication of
AF. Centers that are extensively experienced in
performing AF ablation report long-term success
rates ranging from 75–90%. This paper will review
the mechanism of initiation and perpetuation of AF,
the role of imaging in catheter ablation, various
catheter ablation strategies, complications of AF
ablation, alternative energy sources used for ablation
and new antiarrhythmic drugs (AADs).
Mechanism of Atrial Fibrillation
AF is characterized by the presence of multiple
activation waves within the atria. The mechanisms
by which these activation waves occur have been
hotly debated for many years. The focal source
hypothesis states at a single rapidly ﬁring focus acts
as a driver, causing the rest of the atria to go into AF.
Studies in the 1950s demonstrated that local injec-
tion of aconitine into the atria could result in a
rapidly ﬁring focus that drives the atria into AF.1) A
sustained reentry2) can similar act as a driver and
generates AF. On the other hand, multiple wavelet
hypothesis states that heterogeneity in atrial repola-
rization is responsible for the generation of multiple
wavelets that sustain AF. If true, the multiple
wavelets hypothesis suggests that AF is self-sustain-
ing and does not need a driver. Central to these
hypotheses are thoracic veins, which have been
shown to be highly arrhythmogenic. In 1998,
Haissaguerre et al.3) reported that repetitive rapid
discharges from the pulmonary veins (PVs) were
responsible for triggering AF in a series of 45
patients with symptomatic paroxysmal AF. Radio-
frequency ablation of these PVs foci successfully
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eliminated AF in up to 62% with a median follow-up
period of 7 months.
Humans have a signiﬁcant amount of left atrial
myocardial tissue cardiac muscle which extends into
PVs.4) The myocardial architecture in normal human
PVs is also highly variable.5) In addition, aging may
result in ﬁbrosis at the PV antral (PVA) junctions,
which further produces greater anisotropy in these
veins. Several investigators6,7) have demonstrated
that in animal models, PVs are capable of generat-
ing independent electrical activity. Perez-Lugones
et al.8) examined PV tissue from ﬁve autopsies out of
which four had a history of AF and demonstrated
that under electron microscopy, four out of ﬁve had
morphological features consistent with that of
Purkinje cells in the PVs. It is conceivable then that
triggered activity and/or automaticity may have a
role in initiating and sustaining AF.
In addition, we have come to realize over the
years that other thoracic veins such as the superior
vena cava (SVC), the ligament and/or vein of
Marshall, the coronary sinus musculature are also
highly arrhythmogenic and may play a role in the
initiation and maintenance of AF.
Imaging in AF ablation
Most AF ablation requires LA instrumentation via
transseptal puncture and up to 3 punctures is made
depending on the strategy adopted.9) In most cases,
ﬂuoroscopy provides suﬃcient information for safe
transseptal punctures. However, ﬂuoroscopy may be
limited in the presence of interatrial septal varia-
tions, atrial or aortic root dilatation, prior LA
instrumentation and the need to introduce up to 3
sheaths into the LA. Transesophageal echocardiog-
raphy (TEE) allows identiﬁcation of the fossa ovalis
and its surrounding structures, provides real time
assessment of the procedure, and visualizes tenting
of the fossa ovalis, the subsequent entry and
advancement of the sheath into the LA. However,
the TEE probes obstructs ﬂuoroscopic ﬁeld and is
utilized in only in-anesthetized patient, thereby
preventing periodic neurological assessment of the
patient. Intracardiac echocardiography (ICE) pro-
vides similar information as TEE but it can be used
in a conscious patient and does not obstruct ﬂuoro-
scopy. In addition, phased array transducers allow
visualization of LA structures and a slightly poste-
riorly directed transseptal puncture can be safely
performed to facilitate placement of mapping and
ablation catheters at various PV antrum regions.
The goal of present day ablation strategies is to
electrically isolate the PVs from the rest of the LA.
Importantly, ablation performed at the PV antrum-
LA junction decreases the incidence of PV stenosis.
However, PV anatomy in humans is highly varia-
ble.10) Furthermore, variation in oriﬁce size, orienta-
tion and diameter occurs during the cardiac cycle
and is further accentuated by respiration.11) Given
this marked variability, information on the number
and anatomy of the PV is essential in performing
successful and safe ablation. This can be performed
pre-procedurally using computerized tomography
(CT) or magnetic resonance imaging (MRI). Fur-
thermore, these CT or MRI images can be fully
integrated with Carto (Biosense Webster, Diamond
Bar, CA, USA) or side by side with NavX (EnSite,
St. Jude Medical, St Paul, MN, USA) 3D mapping
system. The clinical usefulness of these 3D mapping
systems during ablation will be dependent on the
accuracy of image integration.
Venography, TEE and ICE can be performed to
provide real time imaging of the PVs. Wood et al.
compared imaging of PV ostial anatomy with CT,
TEE, ICE and venography in 24 patients undergoing
AF ablation.12) CT and ICE were superior to TEE in
identifying the number of PV ostia. Ostial diameter
was overestimated by venography and underestimat-
ed by TEE. Both CT and ICE yielded similar ostial
diameters. This discrepancy could be due to the
elliptical shape of the ostia whereby measurement in
one plane will either under or over estimate its true
diameter. Recently, multislice CT scanning is supe-
rior to ICE in demonstrating the oval shape of the
ostia.13)
ICE is able provide real time assessment of the
PVs and the PVA junction. Titration of energy
delivery during RF ablation by the development of
microbubbles can be performed with this imaging
utility, thereby providing real time information on
lesion formation only in non-open irrigated catheter
ablation systems. Both ICE and TEE are also useful
for monitoring complications within the LA. Its
ability to provide real time imaging identiﬁes LA
appendage, clot formation and the detection of
pericardial tamponade. Recently, ICE allows early
detection of small thrombi formation on the trans-
septal sheath14) that allows appropriate sheath man-
agement to avoid inadvertent dislodgement and a
potential catastrophic thromboembolism.
Catheter Ablation of Atrial Fibrillation
Catheter ablation for the treatment of AF has
evolved over the years. The concept of PV isolation
(PVI), was initially limited to the PVs, and has been
modiﬁed by The Cleveland Clinic to involve the
LA myocardium surrounding the PV to achieve
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complete electrical isolation of the PV antra as a
procedural endpoint, namely the LA-PV antrum
isolation (PVAI).15) In addition to circular mapping
catheter guided PVAI, we electrically isolate further
AF trigger sites, modify the substrate for AF
maintenance, and are possibly modulating cardiac
autonomic tone at various LA, right atrial (RA) sites
and within the coronary sinus to achieve a higher AF
free success rate.
Under light sedation to facilitate periodic neuro-
logical assessment, ICE (10 Fr phased array, Sie-
mens AG Inc., Malvern, PA, USA) guided double
transseptal punctures are performed using Mullins
and SRO sheaths at the midposterior septum,
through which a 10 pole, 20mm diameter circular
mapping catheter and an open irrigated ablation
catheter are introduced respectively. In patients with
severe LA enlargement, a J-curve ablation catheter
is preferred to the usual F-curve ablation catheter.
Heparin boluses are given prior to the ﬁrst and
second transseptal puncture and subsequent heparin
infusion is started to achieve an activated clotting
time > 350 s.
Pulmonary vein antrum isolation
An ablation strategy that only isolates the PV with
spontaneous or provoked AF triggers has been
associated with higher recurrence rates.16) These
ﬁndings led to the current strategy of empirical
PVAI for all 4 PVs without provocative measures,
in an attempt to reduce AF recurrence (Figure 1).
Isolation of the PVs is usually performed in the
following order: left superior, left inferior, right
superior and right inferior. The circular mapping
catheter is placed at the PV antrum-LA junction
deﬁned by ICE. RF ablation is performed at sites
where PV potentials are recorded in the mapping
catheter. With an open irrigated catheter system,
a temperature of 45C and a maximum power of
50W is used. As the PV antrum is a large structure,
multiple movements of the circular mapping catheter
are required to identify potentials at various regions
of the respective PV antra. An esophageal temper-
ature probe is inserted prior to ablation and to titrate
energy delivery during ablation of the posterior wall
of the LA. Energy delivery is halted temporary when
the esophageal temperature exceeds 38.5C. Using
this approach, we are fortunate not to have any cases
of atrio-esophageal ﬁstula thus far. To reduce
ﬂuoroscopy, ICE imaging, ablation artifact on the
circular mapping catheter and 3D mapping systems
(CARTO, NavX) are used as surrogate markers of
catheter position. The end point for PVAI is to
eliminate potentials at the respective PV antra. Entry
block is veriﬁed when no PV potentials can be
recorded at the antrum or within the PV by the
circular mapping catheter. Occasionally, electrical
dissociation of the PV from the LA conﬁrms exit
block. At the end of the procedure, all four PV antra
are extensively remapped to identify remnant or
recovered potentials for ablation to achieve complete
electrical isolation.
Non pulmonary vein ablation
The incidence of non-PV triggers giving rise to
AF has been reported to be approximately 20–32%17)
(Figure 3). The SVC is a common site for non-PV
triggers in patients with paroxysmal AF. In humans,
cardiac excitation has been registered up to 5 cm
above the anatomical junction of the SVC and RA,
deﬁned at the base of the RA appendage.18) It
contains atrial myocytes capable of exhibiting
A B
Figure 1 Anatomic deﬁnition of pulmonary vein ostium and antrum using 3D CT imaging (A) and ICE (B).
Note that the right and left pulmonary vein antra include the posterior wall of the left atrium. LSPV: left superior
pulmonary vein; RSPV: right superior pulmonary vein.
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enhance automaticity and afterdepolarization.19) In a
series of 240 patients who had a total of 359 ectopic
foci initiating AF, 20% originated from non-PV
sites.20) Of which the SVC accounted for 37% of
these non-PV sites either exclusively or otherwise.
RF ablation of the ectopic SVC sites eliminated
paroxysmal AF and up to 86.7% of patients with
exclusive SVC foci were free of AF without AADs.
In our series of 407 patients who underwent catheter
ablation for AF, SVC triggers were identiﬁed in 12%
of the initial 190 patients in the setting of intra-
venous isoprotenerol up to 20 ug/min.21) In view of
this ﬁnding, empirical SVC isolation was performed
in the rest of the 217 patients. 16% of these patients
had recurrence of AF during long-term follow-up.
Of these, 25 patients underwent a repeat procedure
and 5 patients were identiﬁed to have SVC triggers.
Of note 4 out of these 5 patients did not have a
prior SVC isolation. At our centre, empirical SVC
isolation is performed after PVAI. The catheters
and sheaths are pulled into the RA. The SVC is
mapped with the circular mapping catheter at the
lower border of the pulmonary as identiﬁed on ICE.
Isolation of the SVC is then performed at this level.
High voltage pacing at the lateral portion of the SVC
is performed to check for phrenic nerve stimulation
as well. If phrenic nerve stimulation is present, these
sites are precluded from ablation. Otherwise com-
plete isolation of the SVC is performed.
The crista terminalis (CT), a structure in the right
atrium, has been identiﬁed as a source of non-PV
triggers. These triggers appear to be catecholamine
sensitive and have been implicated in the initiation
of AF following cardioversion in patients with
chronic AF, which was observed in 37.5% of our
series of 48 patients,22) with majority of foci arising
from the mid to superior aspect of the CT. In a small
series of 5 patients who underwent PVI and SVC
isolation, non-contact mapping was used to identify
several areas around the crista terminalis, which
have spontaneous activity that initiate AF. Subse-
quent ablation of these sites abolished the CT free of
ectopy-initiating AF.23)
The CS musculature is also an origin of focal
atrial tachycardias. Repetitive rapid discharges from
the CS musculature may be a potential driver for AF
and these triggers have been documented in 2
patients who underwent prior PVI and substrate
modiﬁcation with linear lesions for chronic AF.24)
Electrical disconnection from the adjoining atrial
myocardium permanently eliminated drivers main-
taining AF. Furthermore, electrical isolation of the
CS from the LA has been shown to decrease AF
inducibility in patients with paroxysmal AF.25)
The ligament of Marshall (LOM) is a vestigial
structure of the left primitive veins. It runs from the
CS superiorly on the posterior wall of the LA to the
region near the oriﬁce of the left superior PV. In
some cases, this LOM connects to a small auricular
vein that drains into the CS. This vein is called the
vein of Marshall (VOM). The muscle extensions of
the LOM is complex, with multiple myocardial tract
insertions into the LA free wall and coronary sinus
(CS).26) These myocardial tracts exhibit electrical
activity and may display enhanced automaticity
during isoprotenerol infusion.27) Furthermore, these
ectopic potentials have been recorded and ablated in
the vicinity of the left superior PV in patients with
non-PV triggers. The VOM has also been cannulated
to guide mapping and ablation of LOM ectopic
activity initiating AF.28)
The persistent left SVC (LSVC) may generate
repetitive rapid discharges that initiate AF (Figure 2).
Hsu et al. described the role of persistent LSVC as
the arrhythmogenic source of AF in 5 patients after
PVI.29) The LSVC was electrically connected to the
lateral LA and via the CS to the RA. The CS-LSVC
and LA-LSVC connections were mapped with the
Figure 2 CT angiography with 3D reconstruction of the
heart.
LAO view with caudal angulation showing the relation of the
persistent LSVC to the left atrium, appendage, and pulmonary
veins. Also note the hugely dilated coronary sinus in which the
LSVC as well as the other tributaries drain. TA = Tricuspid
annulus, MA = Mitral annulus, RAA/LAA = right/left atrial
appendage.
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circular mapping catheter and ablation was per-
formed to achieve electrical isolation of the LSVC as
conﬁrmed the LSVC and LA in 4 out of 5 patients.
These 4 patients remained in sinus rhythm as a mean
follow up period of 15 10 months without the need
of any antiarrhythmic drugs. We described a series
of 6 patients with LSVC, 4 of which developed
recurrence of AF post PVAI.30) The PVs of these 4
patients were found to be electrically isolated during
a subsequent repeat procedure. Spontaneous atrial
ectopy was observed in 3 out of 4 patients, of which
AF was initiated in one patient. Circular mapping
catheter guided RF ablation electrically isolated the
LSVC-LA-CS connections. All patients remained in
sinus rhythm without any antiarrhythmic drugs at
mean follow-up period of 13 7 months.
The LA appendage as a source of ectopy for the
maintenance of AF has been described in a single
case report.31) Circumferential ablation of the ostium
of the LA appendage eliminated AF resulting in
complete electrical isolation as evidenced by dis-
sociated trigger potentials originating from the LA
appendage was achieved. At 5 months follow-up
this patient remained in sinus rhythm without any
thromboembolic events while on anticoagulation.
The inferior vena cava (IVC) has rarely been
documented to have AF triggers. A survey of the
literature identiﬁed 3 cases. In two cases, ectopic
activity was mapped to the posterolateral aspect of
the IVC ostium and these were successfully ablat-
ed.32) In a separate report, non-PV triggers after PVI
was mapped to a site deep in the IVC. Focal ablation
guided by a circular mapping catheter eliminated the
trigger and subsequent IVC isolation was performed
at the IVC-RA junction.33)
The sinus node region as a non-PV trigger for AF
following surgical Maze procedure in patients with
chronic AF has been reported. The PVs were found
to be isolated while triggers in the sinus node region
were identiﬁed. Following ablation linear lesions
isolation the triggers, AF was eliminated. Unfortu-
nately, the patient had AF recurrence 3 weeks post
procedure.34)
Substrate Modiﬁcation
A survey of the literature has identiﬁed strategies
in addition to PVI to improve long term success rates
without concomitant antiarrhythmic drugs adminis-
tration. These strategies include extensive or limited
linear lesions, ablation of complex fractionated atrial
electrograms, regions that display dominant frequen-
cy during atrial ﬁbrillation and ablation of autonomic
ganglionated plexuses. The following section aims to
review the rationale of these strategies, its applica-
tion and clinical outcome.
Linear ablation
Biatrial surgical Maze procedure pioneered by
Cox et al. was eﬀective at segmenting the atria to
prevent the occurrence of reentrant activity. Sub-
sequently, modiﬁcation in this surgical procedure
was able to achieve up to 95% success rate at long
term follow-up with equivocal results between
patients with or without structural heart disease and
in paroxysmal or persistent AF.35) This surgical
technique forms the basis for percutaneous catheter
based techniques in substrate modiﬁcation.36) Linear
lesions were placed in both RA and LA. Although
eﬀective, this percutaneous catheter based Maze
strategy was limited by long procedural time, high
thromboembolic risk and potential proarrhythmia
due to incomplete lesion continuity between ana-
tomical obstacles. Adjunctive linear ablation follow-
ing PVI has been assessed in patients with either
paroxysmal or persistent. AF. Haissaguerre and
colleagues37) performed linear ablation with an open
irrigated catheter system to join the superior PVs,
which then connect to the anterior mitral annulus in
addition to a cavotricuspid isthmus ablation. Com-
plete linear block was achieved in 14 patients (58%)
of which 9 (64%) remained AF free without anti-
arrhythmic drugs at 28 4 months of follow up. Of
those who did not achieve complete linear block,
only 30% remained AF free. Subsequently, the same
investigators assessed the eﬃcacy of mitral isthmus
Figure 3 The predominant non-PV trigger sites responsible
for initiation of AF are indicated in this segmented 3D contrast
cardiac CT of a patient presenting for AF ablation.
LAA = left atrial appendage; LAPW = left atrial posterior wall;
LOM = ligament of Marshall; CS = coronary sinus; SVC =
superior vena cava; SN = sinus node; CT = crista terminalis;
IVC = inferior vena cava. The persistent left SVC is also a
potential trigger site.
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ablation in patients with paroxysmal AF following
PVI. Mitral isthmus conduction block was achieved
in 88% of the patients, but this approach often
required ablation within the CS. This adjunctive
ablation strategy safely increased success rate to
79%.38) The strategy of adjunctive LA roof linear
lesions and mitral isthmus ablation in addition to
wide area circumferential PV ablation has been also
demonstrated to eﬀective.39) Ernst et al. created one
of four linear ablation conﬁgurations with a 4mm tip
catheter using the CARTO electroanatomic mapping
system. The long-term success rate in patients with
completed linear lesions reached 76%.40)
The Cleveland Clinic performs SVC isolation as
an adjunct approach to ICE-guided PVAI. This has
been shown to be safe and eﬀective strategy in
treating patients with all paroxysmal, persistent or
permanent AF.41) This approach has accounted for a
long-term success rate of 85.4% in paroxysmal AF
and 74.9% in persistent/permanent AF.42) A repeat
procedure increases the success rate to 94.6% and
92.9% respectively (Figure 4).
Complex fractionated atrial electrogram ablation
Complex fractionated atrial electrogram (CFAE)
during AF as a substrate modifying strategy has been
studied. These CFAEs have ﬁrst been identiﬁed
during surgical epicardial mapping as sites exhibit-
ing slow conduction, functional conduction block
and with pivot points.43) These complex electrical
activities exhibit short cycle lengths and heteroge-
neous temporal and spatial patterns.44) Mapping and
ablation of CFAEs has been performed in patients
with PAF and chronic AF.45) CFAEs were deﬁned as
fractionated atrial electrograms (EGMs) with two or
more deﬂections and atrial EGMs with cycle length
<120msec (averaged over 10 seconds). The CAR-
TO system was used for electroanatomic correlation,
dividing the RA and LA into nine distinct areas.
Based on CFAE distributions three types were
described: Type I CFAEs were found in only one
area and focal ablation terminated AF; Type II in
two areas; Type III required three or more areas of
ablation (PV was one area regardless of how many
PVs expressed CFAEs). CFAE ablation terminated
AF in 95% patients (28% required concomitant
ibutilide). Type III distribution was more commonly
identiﬁed in patients with chronic AF. The interatrial
septum was the most common site for CFAEs, which
were not present in the appendages. At the 1-year
follow-up, 91% patients were free of arrhythmias
and symptoms, with 20% requiring a second proce-
dure.
Ablation targeting dominant frequency sites dur-
ing atrial ﬁbrillation
Previous investigators have observed that admin-
istration of antiarrhythmic drugs can decrease the
frequency of ﬁbrillatory waves in the surface ECG.
A low dominant frequency (DF) associated with a
high degree of organization predicts a higher success
rate for electric cardioversion of AF. Such observa-
tions were seen in intracardiac recordings of isolated
sheep hearts under acetylcholine infusion. In addi-
Figure 4 Pulmonary venous (PV) isolation at their antrum aspect is shown in this segmented 3D contrast cardiac CT of another
patient presenting for AF ablation.
Panel A illustrates the placement of RF lesions at the PVs antrum and at the SVC. Note the lesions’ continuity along the posterior wall and
at the anterior aspect of the LA roof. Panel B: PV antra (dotted circles) seen from the superior view. Also, note the close proximity of the
SVC to the right superior PV (RSPV) and the circumferential lesion created for SVC isolation. LSPV = left superior PV; LIPV = left
inferior PV; RIPV = right inferior PV; RAA = right atrial appendage.
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tion, Jalife et al. provided evidence for spatiotem-
poral organization due to the presence of AF. They
also reported a variable DF between the intracardiac
mapping sites and sites with the highest DF are
regarded as source of AF. In a series of 32
patients,46) frequency mapping identiﬁes localized
sites of high frequency activity during AF in humans
with diﬀerent distributions in paroxysmal and per-
manent AF. Patients with paroxysmal AF frequently
harbored DF within the PVs. Ablation of these DF
sites slowed and terminated 87% of patients with
paroxysmal AF but none in those with permanent
AF. Spectral analysis and frequency mapping can
identify high-frequency activity potentially correlat-
ing with rotors responsible for the maintenance of
AF.47) The eﬃcacy of this novel strategy for AF
ablation remains to be shown prospectively using
real-time spectral analysis.
Ablation of autonomic ganglionated plexuses
Localization and ablation of autonomic ganglio-
nated plexuses (GP) in the LA have been evaluated
in animal and clinical studies (Figure 5). The GPs,
present in epicardial fat pads, were identiﬁed by
high-frequency stimulation (HFS—at PCL 50msec,
12V, PW 1–10msec) at the PV and PVA (endocar-
dial and epicardial sites). A positive response to HFS
was indicated by induction of AF and/or increased
vagal tone leading to bradycardia or AV block. HFS
identiﬁed GPs at four distinct locations (Figure 3):
anterior to the right PVs, inferior to the RIPV (right
inferior pulmonary vein), superior and medial to the
LSPV, and inferior to the LIPV. For GPs ablation,
a median of 2–6 RF applications was required to
eliminate the vagal response to HFS. Interestingly,
GPs ablation abolished PV ﬁring in 95% of patients,
but did not aﬀect sustained AF inducibility either
prior to or following PVAI.
In the 33 patients undergoing this combined
approach, all patients with PAF and 81% with
persistent were AF free at a median follow-up of 5
months.48) The same investigators had observed that
GPs are commonly located within three major CFAE
areas of the LA.49) They have also shown that GP
stimulation can automatically induce conversion of
PV focal ﬁring to AF and that this response is
eliminated by injecting neuronal blockers into the fat
pad.50) Experimental and clinical ﬁndings suggest
that LA autonomic denervation targeting GPs may
downregulate PV ﬁring and suppress AF inducibil-
ity. In our clinical experience with HFS, the GP sites
identiﬁed by vagal response were tagged and blinded
to the operator performing ablation. Following our
standard PVAI procedure without targeting the GPs,
vagal response was abolished in all patients. This
suggested nonintentional GP modulation during
PVAI. Interestingly, in another group of patients
presenting with recurrent AF following PVAI, HFS
failed to produce vagal response in all patients.51)
We have also assessed the long-term eﬀect of GPs
ablation in a canine model and found that the
denervation eﬀects achieved by ablation had dis-
appeared on repeat evaluation at 4 weeks postabla-
tion.52)
Optimizing the cure of atrial ﬁbrillation
The reported successes with various ablation
strategies underlie the complex pathogenesis of AF.
Diﬀerent centers have utilized various combination
ablation strategies to further improve the success
rate. Linear LA lesions across areas of CFAE as an
adjunct to LA circumferential ablation have been
studied in a series of 100 patients with paroxysmal
AF.53) Following LA circumferential ablation to
encircle the left and right-sided pulmonary veins
during AF, with additional ablation lines in the
posterior left atrium and mitral isthmus with an 8-
mm-tip catheter were performed. After completing
this lesion set AF was still present or induced in 60%
of patients. These patients were randomized to either
no ablation (Group 2, 30 patients) or further addi-
tional ablation lines (Group 3, 30 patients) along the
left atrial septum, roof, and/or anterior wall targeting
fractionated electrograms. At 6-month follow-up,
67% of patients in group 2 were free of AF without
drug therapy compared with 86% of patients in
group 3 (p ¼ 0:05).
Figure 5 The four regions containing the ganglionated
plexuses (GP) are illustrated in a segmented 3D contrast
cardiac CT.
The GPs are identiﬁed by induction of AF and/or increased vagal
tone leading to bradycardia or AV block during high-frequency
stimulation. ARGP = anterior right GP; IRGP = inferior right
GP; SLGP = superior left GP; ILGP = inferior left GP.
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The same investigators randomized 80 patients
with chronic AF to either LA circumferential
ablation (n ¼ 40) or nonencircling linear ablation
(n ¼ 40).54) In LA circumferential ablation, the PVs
were encircled, with additional lines made in the
mitral isthmus and posterior wall or roof. In non-
encircling linear ablation, 4 1 ablation lines were
created targeting areas of complex electrograms with
the objective of voltage abatement. Linear lesions
were created in the roof, anterior wall, septum,
mitral isthmus and posterior annulus. At 9 4
months follow up, 68% of patients who underwent
LA circumferential ablation remained free of AF
without the need of antiarrhythmic drugs compared
to 60% of patients who underwent nonencircling
linear ablation.
A stepwise ablation curative approach with high
incidence of AF termination has been evaluated in
60 patients with long lasting persistent AF.55) A
randomized ablation sequence including PVI, SVC,
and CS isolation and atrial ablation at sites exhibit-
ing continuous electrical activity or CFAE termi-
nated AF in 53% of patients. The addition of linear
lesions at the LA roof, mitral isthmus, and cavo-
tricuspid isthmus accounted for AF termination in a
total of 83% of patients. Termination of AF to either
atrial tachycardias or sinus rhythm was typically
preceded by lengthening of AF cycle length. Only
13% of patients converted directly to sinus rhythm,
while the majority developed atrial tachycardias.
Activation and mapping entrainment was subse-
quently performed to identify its mechanism. Focal
atrial tachycardias were localized to the PVs, LAA,
and CS and these sites were subsequently ablated.
All focal atrial tachycardias were interrupted with up
to 2 RF applications. Macroreentrant atrial tachy-
cardias utilized the mitral isthmus, LA roof or the
cavotricuspid isthmus and linear lesions were created
at these sites. The LAA, CS, and PV-LA junctions
contained the initiators of AF in most patients.
Lesser critical LA structures included the roof,
septum, posterior wall, and mitral isthmus. However,
24 (40%) patients developed atrial tachycardia by 3
months out of which 22 were sustained AT. Of these,
23 underwent repeat procedure of 55 ATs. 4 patients
required 3 procedures in total. In these 23 patients,
focal AT was localized to similar sites as identiﬁed
by the ﬁrst procedure. Similarly, macroreentrant ATs
utilized the gaps or recovered conduction of previous
linear ablation at the mitral isthmus, LA roof or
cavotricuspid isthmus. With this approach, 95% of
patients remained in sinus rhythm at 11 6 months
of follow-up with majority of them without taking
any antiarrhythmic drugs.
At the Cleveland Clinic, AF nest ablation guided
by real-time spectral mapping in SR as an adjunctive
approach to ICE-guided PVAI and SVC isolation has
been evaluated in a randomized. Real-time spectral
mapping using fast Fourier transform (FFT) in SR
has identiﬁed atrial sites with unusually high
frequencies, namely, ﬁbrillar myocardium or AF
nest56) at the LA appendage, left intraatrial septum,
inferior posterior LA along the mitral annulus,
SVC/RA junction, crista terminalis and the CS os
(Figure 6). The AF nests may exhibit anisotropic
conduction and short refractoriness. This highly
resonant tissue may harbor sites expressing CFAE
during AF. Ablation of atrial tissue identiﬁed as AF
nests as a sole approach without intentional PVI, has
maintained SR in 94.1% patients at 9:9 5 months
follow-up. However, 41.1% remained on previously
ineﬀective AAD. Importantly, full lesion thickness
is not required to normalize the spectrum and may
be less likely to create a substrate for macroreentrant
ATs while sparing viable atrial myocardium. RF
delivery for 20–30 seconds typically abolishes the
high-frequency potentials and normalizes the spec-
trum of the local bipolar EGM. This approach may
be preferable to targeting continuous electrical
activity or CFAE sites that may be unrecognized
due to their temporal variability. We have been
evaluating the adjunctive role of empirical ablation
of typical AF nest regions in addition to ICE guided
approach to PVAI and SVC isolation in a pro-
spective randomized study. Initial results of 157
patients with persistent or paroxysmal AF were
promising. We randomized these patients to either
PVAI + SVC isolation + empirical ablation of
typical AF nest regions (group 1) or conventional
PVAI and SVC isolation (Group 2). The ablation
strategy for patients in Group 1 was safe and resulted
in signiﬁcant reduction of AF recurrences as com-
pared to group 2. We eagerly await completion of
this study.
Complications of Catheter Ablation of Atrial
Fibrillation
Extensive ablation within the atria coupled with
instrumentation with various catheters in the setting
of aggressive anticoagulation during AF ablation sets
the stage for potential complications. A variety of
these complications have been reported and some of
them have been fatal. While the majority occurred
during or within 48 hours of the procedure, some are
known to have an insidious course. This section
reviews these complications with an objective to
suggestive preventive and deﬁnitive measures.
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Cerebrovascular events
The incidence of thromboembolism in AF ablation
ranges from 0.5 to 2.8%.57) A worldwide survey
reported periprocedural deaths due to massive
cerebral thromboembolism in two patients out of
8745 patients.58) Prevention remains the best strategy
in reducing thromboembolic events during AF
ablation. At our centre, warfarin therapy is not
discontinued prior to ablation. If patients with
persistent AF arrive to the EP laboratory with a
non-therapeutic INR, a TEE is performed prior to the
ablation procedure to exclude any intra-atrial clots.
Prior to the ﬁrst transseptal puncture, a bolus of
heparin of about 100mg/kg is given and an infusion
is started to maintain an ACT of 400 to 450 s. Both
transseptal sheaths are continuously perfused with
heparinized saline and meticulously ﬂushed when
catheters are exchanged. In addition, we minimize
char formation during lesion creation by titrating
power delivery to prevent abrupt impedance rise.
ICE is routinely used for early detection of intra-
cardiac thrombi. Despite these measures, we report
a cerebral thromboembolic rate of 0.6% in 3060
patients who underwent PVAI at our centre (unpub-
lished data). Only two deaths were reported, one
within one month and the second death occurred 4
years after the procedure. The rest of the patients
experienced full neurological recovery.
PV stenosis
The incidence of PV stenosis, deﬁned as >70%
narrowing, was reported to occur in 3.4%59) of
patients. The pathogenesis of PV stenoses is due to
an initial ablative insult that precipitates a healing
reaction culminating in an endovascular contraction
and proliferation of elastic lamina/intima. The
incidence of PV stenosis has decreased due the
current technique of PVAI that targets antra far from
PV ostia. Clinical diagnosis of PV stenosis is often
diﬃcult and a high index of suspicion is required.
Figure 6
Panel A: The typical locations exhibiting ﬁbrillar myocardium (AF nest) during real-time spectral mapping in sinus rhythm,
following PVs and SVC isolations, are shown in a segmented 3D contrast cardiac CT of a patient presenting for AF ablation. Note
in Panel B, the frequency spectra of two consecutive bipolar electrograms recorded from the CS (arrow in Panel C). The high-
frequency components characteristic of AF nests are indicated by the arrow in Panel B. Radiofrequency delivery up to 35W for
20 seconds eliminated the ﬁbrillar pattern (shown in Panel D).
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These patients present a variety of respiratory
symptoms, including cough (89%), hemoptysis
(63%), dyspnea (58%), pleuritic chest pain (58%)
and wheezing (42%).60) However up to a third of
patients with severe PV stenosis remained asympto-
matic while symptomatic patients were erroneously
diagnosed as having pneumonia, new onset asthma,
pulmonary embolism and/or lung cancer. At present,
the gold standard for diagnosis of PV stenosis is
spiral computed tomographic angiogram and/or
magnetic resonance. In a series of 23 patients with
severe PV stenosis, balloon angioplasty alone or
with stenting immediately relieved symptoms.
However, in-stent or in-segment stenosis occurred
in 61% of patients during a 17-month follow-up.61)
Neumann et al.62) reported the long-term outcome of
primary angioplasty versus primary angioplasty with
PV stenting for symptomatic severe PV stenosis in
12 patients with a total of 15 PV stenoses. PV
stenting resulted in no restenosis over the 12-month
follow-up while those who underwent PV angio-
plasty had a high recurrence rate of 73%.
We recently described 18 patients who progressed
to total PV occlusion, deﬁned as 95% stenosis or
complete loss of patency of the PV on CT scan.63) Of
1,780 patients who underwent AF RF ablation during
the period of 1999 to 2004 at our institution, 16
(0.9%) were found to have pulmonary vein occlusion
(PVO) of at least 1 PV, whereas 2 additional patients
were referred from other institutions for further
evaluation and management of their occluded PVs.
The clinical presentation of these patients was
variable; 4 (22.2%) patients were totally asympto-
matic throughout their course (deﬁned as grade 0), 2
(11.1%) had mild symptoms of dry cough or dyspnea
on moderate/severe exertion (NYHA class I;
grade 1), 4 (22.2%) had moderate symptoms of
dyspnea on mild exertion (NYHA class II/III),
together with persistent cough (grade 2). Three
(16.7%) patients had severe symptoms as severe
dyspnea (NYHA class III/IV) with hemoptysis,
fever, or pleuritic chest pain (grade 4) at their initial
presentation, whereas 5 other patients (27.8%). CT
scan identiﬁed a total of 24 occluded veins in 18
patients, with a mean of 1.4 veins per patient. Of
these 24 occluded veins, the left superior PV had the
greatest incidence of occlusion (54.2%), followed
by the left inferior PV (29.2%), right inferior PV
(8.3%), and the right superior PV (8.3%). By
considering the total venous drainage of each
independent lung, the percentage of stenosis of the
aﬀected veins on the same side were added together
to yield an average cumulative stenosis of the
vascular cross-sectional area draining the aﬀected
lung (cumulative stenosis index [CSI]). CSI = sum
of percent stenosis of the unilateral veins divided by
the total number of ipsilateral veins. We concluded
that patients with a CSI  75% and a relative lung
perfusion of 25% based on lung perfusion scan
have the greatest risk of severe symptoms and lung
diseases. In these patients, early and, when required,
repeated PV intervention should be considered for
restoration of pulmonary ﬂow and prevention of
associated lung disease.
Esophageal injury and ﬁstula
The posterior wall of the LA is adjacent to the
esophagus and RF ablation procedures may substan-
tially elevate the temperature within the esophageal
lumen (Figure 7). Atrial-esophageal ﬁstulas may
result from this thermal injury leading to tissue
necrosis. Esophageal damage, perforation, and atrio-
esophageal ﬁstulas were ﬁrst described after poste-
rior left atrial radiofrequency ablation performed
during open-heart surgery.64) Subsequently, three
patients with this complication after percutaneous
radiofrequency catheter ablation from experienced
centers were published in 2004.65,66) We reported
a series of 9 patients who had this devastating
complication via an anonymous volunteer reporting
method.67) Clinical presentations occurred within
about 2 weeks of the ablation procedures (mean, 12
days [range, 10 to 16 days]). Patients presented with
general malaise, leukocytosis, and persistent fever of
undetermined origin. All patients developed septic
shock and cardiovascular collapse. Eight patients
had neurologic ﬁndings consistent with multiple
embolic strokes. Of these, 2 had intravascular air
on computed tomography. Six patients had echocar-
diograpic features of endocarditis. Two patients
presented with symptoms consistent with transient
angina associated with ST-segment elevation on
electrocardiography. Three patients reported sub-
stantial gastrointestinal bleeding, but ﬁve patients
had occult bleeding documented by fecal testing.
Unfortunately, all 9 patients died and autopsy
conﬁrmed the presence of atrioesophgeal ﬁstula.
Although atrioesophageal ﬁstula formation is
apparently rare, it seems to almost always be fatal.
Therefore, evaluation and management of patients
presenting with this potential complication must
focus on rapid diagnosis and triage. Fever, malaise,
leukocytosis, dysphagia, and neurologic symptoms
in patients with a recent catheter ablation procedure
should raise suspicion of atrioesophageal ﬁstula. The
diagnosis must be rapidly conﬁrmed by noninvasive
imaging techniques, including transthoracic echo-
cardiogram, magnetic resonance imaging, or com-
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puted tomographic scan, especially when combined
with water-soluble contrast.68) Any form of esoph-
ageal instrumentation should be avoided in these
patients. Once diagnosed, prompt surgical interven-
tion is required. Recently, a case of successful
temporary esophageal stenting to seal oﬀ the
esophageal perforation following LA catheter abla-
tion was reported.69)
We studied the inﬂuence of LA ablation by
measuring intraluminal temperature via an esopha-
geal thermometer in 81 patients who underwent
PVAI.70) The esophageal intraluminal temperature
was signiﬁcantly higher when ablation was per-
formed at the posterior LA, adjacent to the esoph-
agus. This was also associated with microbubbles
generation detected by ICE. We concluded that
titration of RF delivery with ICE in non open
irrigated catheter systems and/or continuously mon-
itoring esophageal temperature may be an option to
enhance safety for posterior LA wall ablation. Since
utilizing this strategy, we report no atrioesophageal
ﬁstulas. Alternative strategies in visualizing the
esophagus during AF ablations include ingestion of
Gastrograﬁn dye, tagging the esophagus on 3D
electroanatomic mapping system and merging 3D
recreated image of the esophagus with an electro-
anatomic shell of the LA.
Pericardial effusion and cardiac tamponade
Pericardial eﬀusion is not uncommonly observed
in patients undergoing AF ablation. However, the
reported incidence of cardiac tamponade is 1.22%
(Worldwide survey of AF ablation). The common
mechanisms include cardiac perforation by various
catheters or steam pops. We identiﬁed 26 (7.4%) out
of 352 patients who had steam pops over a three-
month period during RF ablation for AF.71) There
were 44 steam pops at these locales: left interatrial
septum (36.4%), PVA area (20.5%), right atrium
(18.2%), left atrial roof (11.4%), left atrial posterior
wall (6.8%), mitral annulus (4.5%) and left atrial
anterior wall (2.3%). Majority (>90%) of pops
occurred with the catheter orientated perpendicularly
to the tissue. Seventy-ﬁve percent of these pops
occurred with a power  35W, temperature  39C
and impedance  90 ohms. There was not an ob-
servable decrease in impedance prior to steam pops
and no acute procedural complications. Preventive
strategies include titrating RF energy to prevent
sudden impedance rise during ablation. In open
irrigated catheter systems, we do not observe such
rise in impedance prior to the occurrence of steam
pops. Titrating RF energy to prevent sudden rise in
catheter tip temperature may be a more practical
option.
Organized atrial tachyarrhythmias
Left atrial tachycardia (AT) following segmental
or wide area circumferential PVI and LA circum-
ferential ablation with additional linear ablation has
been variably reported as ranging from 2.5% to 27%.
The mechanism of these ATs has been described as
macroreentry AT due to reentry related to gaps in the
linear ablation line. These gaps have been identiﬁed
as a slow conduction isthmus in the reentry circuit
primarily located at the LA posterior wall or mitral
isthmus. These macroreentry ATs are often sympto-
matic necessitating a repeat ablation. On the other
hand, focal ATs typically originate from PV ostial
segments that have partially recovered conduction
Figure 7 Three-dimensional computed tomographic reconstruction of the left atrium in relation to the
esophagus.
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to the LA. Of note, centers that adopt a strategy of
wide area circumferential PV ablation and linear LA
ablations72,73) appear to experience an increased
prevalence of AT. This may imply that the inability
to create contiguous linear lesions and/or recovery
of partial conduction along such lesions can be
proarrhythmic. We adopt the strategy of PVAI
without empirical linear lesions in the LA in an
eﬀort to minimize the incidence of iatrogenic AT in
our centre.
Phrenic nerve injury
Phrenic nerve injury (PNI) is a rare complication
that may occur as a result of diﬀerent catheter
ablation procedures. The course of the right phrenic
nerve is lateral and slightly posterior to the SVC and
RA, and descends anteriorly to the right superior
PV near the right superior PV-LA oriﬁce alongside
of the pericardium, anterior to the lung hilum before
reﬂecting into the right diaphragm.74) Sanchez-
Quintana et al.75) showed that the minimum distance
between the right phrenic nerve and the right
superior PV or SVC was shorter than that between
the right phrenic and right superior PV-LA or SVC-
RA junction.
We studied 17 patients who sustained PNI
following catheter ablation with a variety of energy
sources including RF ablation (13 patients), cryoa-
blation (1 patient), ultrasound balloon ablation (2
patients) and laser balloon ablation (1 patient).76)
Two patients with RF ablation-induced transient
right phrenic nerve paresis were detected on ﬂuoro-
scopy during energy delivery. Diaphragmatic move-
ment spontaneously recovered upon cessation of RF
delivery. The temporal correlation with onset and
oﬀset of energy delivery and the observed transient
nerve dysfunction may suggest a current mediated
electromagnetic eﬀect. RF currents can alter the
action potential duration and amplitude of the nerve,
thus producing a conduction block before injury
takes place.77) Symptoms of PNI are variable
depending on patient’s preexisting lung condition.
Fifty percent of our patients were asymptomatic
while the majority of the remaining patients had mild
symptoms and did not need special therapy. Only
two patients developed lung complications that
required respiratory treatment. In our experience,
all patients who suﬀered from persistent PNI due
to catheter ablation clinically recovered within a
median time of 6 months.
Early detection of transient PNI by ﬂuoroscopy
could result in fewer cases of persistent PNI. While
high-output pacing prior to ablation in certain cases
is a valuable tool to prevent phrenic nerve damage,
the most eﬀective way is to deliver energies away
from the phrenic nerve. Ablation at the level of the
PV antrum or the SVC-RA junction when perform-
ing isolation of these veins for AF could represent a
potential strategy to minimize the risk of PNI. A
novel method of protecting the phrenic nerve during
epicardial catheter ablation by using a balloon
catheter in the pericardial space to mechanically
separate the left phrenic nerve from the ablation
catheter has been recently reported.78)
Other complications of extracardiac damage in-
cluded four patients in whom acute pyloric spasm
and gastric hypomotility were observed following
posterior LA lesions.79)
Energy Sources for AF Ablation
Radiofrequency ablation is widely used in catheter
ablation of atrial ﬁbrillation. The placement of
ablation lesions may be tedious and time consuming
especially in patients with persistent AF. Contact
with the atrial tissue is paramount to eﬀective energy
delivery for creation of transmural lesion. As such,
non-transmural lesions in linear ablations are proar-
rhythmic to macroreentrant atrial tachycardias. The
risk of thrombus formation occurs especially when
the electrode-tissue interface exceeds 80C. With
RF ablation there is a risk of cardiac perforation
associated with the use of high power in the LA.
Such limitations create an impetus to develop
technologies that use alternative forms of energy
delivery. Any technology that can create uniform
and transmural lesions, decreases the need of contact
to deliver suﬃcient energy, reduces procedure time
and improves safety (Table 1).
Ultrasound energy
Ultrasound propagates sound waves at 2 to
20MHz to cause oscillation of molecules and atoms
for heat generation. Ultrasound energy decreases
proportionally with distance, unlike that of RF
energy that decreases by the square of the distance.
Perhaps, the main advantage is its ability to be
collimated as it passes through a ﬂuid media. This
forms the basis of a High-Intensity Focused Ultra-
sound Balloon Catheter (HIFU-BC) for PVAI in
patients with AF. A feasibility study including 27
patients with AF has just been reported.80) The 14 Fr
HIFU-BC has been developed to simplify PVAI with
lower risk of thrombus formation, PV stenosis and
left atrial perforation.81) It uses a parabolic water-
carbon dioxide balloon interface to focus a 20, 25
or 30mm diameter ring of ultrasound 2 to 6mm
forward of the balloon to produce a circumferential
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transmural LA lesions with each application. The
HIFU-BC successfully isolated all PV antra in 74%
of patients. At 12 months follow-up, 57% of patients
were free of symptomatic atrial arrhythmias. There
were no PV stenosis or thromboembolic complica-
tions. One patient sustained pulmonary hemorrhage
due to perforation of the lingular branch of the left
superior PV during manipulation of the guidewire.
There was a case of phrenic nerve palsy in a patient
with a usually large right superior PV. The main
advantages were low risk of thromboembolism since
no direct heating of blood occurs to form thrombus.
Internal irrigation of the balloon also minimizes
formation of thrombus on its surface. Complete
circumferential contact is not required for lesion
placement. The limitations include the need to
position the HIFU-BC over a guidewire necessitating
instrumentation of individual PVs, non-deﬂectable
and diﬃculty in completely sonication of the left
PVs as the balloon often extended over the LA
appendage ridge, leaving a small segment non-
isolated. Improvement in the design incorporating a
deﬂectable curve may produce better results.
Cryoablation
Cryoablation causes direct cell injury and induces
vascular mediated tissue injury. The advantages
include minimal endocardial disruption with preser-
vation of underlying tissue architecture, less platelet
activation, lower thrombogenicity and stable adhe-
sion of the catheter to the tissue during freezing.
Recent clinical studies82) have shown that trans-
venous cryoablation is a safe and feasible method for
PV isolation with acute procedural success compa-
rable to conventional RF ablation. Although the
long-term success rate appeared to be lower,83) no
patients developed PV stenosis. Further reﬁnement
of catheter designs to improve/increase tissue con-
tact surface area or delivery of lower temperature
may improve its eﬃcacy.
Microwave energy
Microwave generates heat by inducing oscillation
of dipoles in a medium such as water. Hence, tissue
with high water content will allow better energy
transfer and heat generation. This may be useful in
scarred myocardium, as viable myocardium will be
Table 1 Features of diﬀerent energy sources for catheter ablation of atrial ﬁbrillation.
Radiofrequency Cryothermy Laser Microwave Ultrasound
Clinical Experience +++ ++ + + +
Potential for High Lower Low Low/medium Low
endocardial
disruption
Thrombogenicity High Low High Medium Medium
Mapping capability Limited Yes No No No
Ability to Create Requires optimal Requires Requires Optimal Required
transmural lesions contact optimal contact optimal contact and optimal
contact orientation Orientation
preferred
Lesion size ++ ++ +++ +++ ++
Linear lesion ++ + ++++ ++++ +
Perforation rate Low Low High Low Low
Procedure time Short Long Short Medium Short
Injury to adjacent structures:
Phrenic nerve ++ /+ +/ ++ +++
Esophagus +++  +/ + +++
Coronary artery +++    
PV stenosis
Other advantages +++ Lack of Combined with Combined with
electromagnetic ﬁberoptic ultrasound
interference catheter for system for
direct lesion direct lesion
visualization visualization
+ = Positive;  = negative
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preferentially heated, creating deeper lesions with
less surface heating and subsequent endocardial
disruption or coagulation formation. Unlike RF
ablation in which lesion expansion was minimal
after 60 s, the depth of microwave lesion size could
still expand in depth.84) This may potentially damage
adjacent structures such as the esophagus, phrenic
nerve and coronary arteries. Although tissue contact
with the catheter is of less importance, a parallel
antenna orientation to the tissue is required for
eﬀective heating.85) Microwave ablation in the
surgical treatment of AF has been proven to be safe
and eﬀective with similar clinical eﬃcacy compara-
ble with conventional RF ablation.86) However,
currently there is limited data on transvenous micro-
wave catheter ablation and it remains an investiga-
tional product.
Laser energy
Laser (light ampliﬁcation by stimulated emission
of radiation) emits photons in a monochromatic
coherent beam. Absorption of laser energy creates
heat by induction of oscillation in water molecules.
It could potentially create deeper lesions with
reduced coagulum formation. In experimental mod-
el, lesions created are sharply demarcated without
epicardial crater or endocardial thrombus formation.
Laser energy delivery requires a ﬁberoptic system
that can double up as an angioscopy. Diode laser is
a low energy laser with a wavelength of 980 nmesc.
Using a linear diﬀuser, linear ablation can be de-
livered. Recently, a laser balloon catheter has been
designed to allow PV isolation by delivering circular
beams of energy at the PV antra. However, clinical
experience in humans is scarce and the use of laser
energy in a ﬁberoptic balloon catheter ablation for
PV isolation remains an investigational tool.
New Antiarrhythmic Agents for Treatment
of AF
Dronedarone
Dronedarone is a new synthetic non-iodinated
derivative of amiodarone undergoing phase III clin-
ical trials. Similar to amiodarone, dronedarone
possesses in vitro electrophysiologic characteristics
of all four classes of antiarrhythmic action. Specif-
ically, it blocks sodium channels at rapid pacing
rates, prolongs cardiac action potentials and refrac-
toriness, and possesses Caþþ antagonistic properties.
Additionally, dronedarone shows a non-competitive
antiadrenergic action. Dronedarone at the dose of
400mg twice daily was eﬀective in preventing both
symptomatic and asymptomatic recurrences of atrial
ﬁbrillation or atrial ﬂutter and had a safety proﬁle
similar to that of placebo.87) The added advantage
was an absence of thyroid and lung side eﬀects.
Moreover, there was no proarrhythmic eﬀects or
torsades des pointes seen and its eﬀect on QT
prolongation is at most modest.88) However, in the
ANDROMEDA trial, patients with recent class III
or IV congestive heart failure and left ventricular
ejection fraction < 35% had an excess mortality
with dronedarone therapy vs placebo, leading to
early discontinuation of the trial. Hence, further
experimental studies and long-term clinical trials are
required to provide additional evidence of eﬃcacy
and safety of dronedarone.
Azimilide
Azimilide is another investigational Class III
antiarrhythmic agent. It blocks the slow delayed
rectiﬁer potassium current (IKs) in addition to the
rapid delayed rectiﬁer outward potassium current
(IKr). Initial studies showed promising results in
prolongation in the time to the ﬁrst recurrence of AF
or atrial ﬂutter compared with placebo with accept-
able risk of torsade de pointes (0.9%) and early
reversible severe neutropenia (0.2%).89) However,
recent trial showed otherwise. 658 patients with
symptomatic persistent atrial ﬁbrillation were
randomized to either placebo, azimilide or sotalol
and all received planned cardioversion.90) Median
time to AF recurrence was 14 days for azimilide, 12
days for placebo, and 28 days for sotalol. Of note, 5
patients on azimilide developed torsades de pointes
and marked QTc prolongation occurred in 3.5% of
patients on sotalol and 7.6% on azimilide resulting in
interruption of the study. These investigators con-
cluded that azimilide is slightly inferior to sotalol
with at modest antiarrhythmic eﬀect, thus limiting its
administration for the treatment of AF.
Future Directions
Curative AF ablation requires signiﬁcant expertise
in operator skills, various ablation tools and imaging
to deliver safe and eﬀective therapy. It will be ideal
to pursue tools to shorten procedure time while
delivering eﬀective lesions safely, thereby avoiding
potentially life threatening or limiting complications.
Remote magnetic navigation (Stereotaxis, Inc., St.
Louis, MO, USA) and the robotic steerable guide
catheter (SGC, Hansen Medical, Inc., Palo Alto, CA,
USA) are two technologies that could greatly
facilitate movement of intracardiac catheter. Re-
search on diﬀerent energy delivery systems is
ongoing and we are hopeful of an ablation tool that
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creates larger area of lesions in a controlled fashion.
Ablation strategies incorporating a combination of
PV isolation and various forms of substrate mod-
iﬁcation for treatment of persistent AF are under
investigation.
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